Patients with SSc have the highest mortality among the rheumatic diseases. In addition, SSc is associated with disfigurement, hand contractures, fatigue, poor sleep, severe RP with numbness and tingling of the fingers can lead to decrements in quality of life. This Points to Consider article provides practical considerations for design of trials for functional disability and other health-related quality-of-life issues.
Introduction
Chronic diseases often have a relapsing and remitting course and have substantial impact on function and well-being [1, 2] . For chronic illnesses where there is no cure, survival is not the only important end point. It is important to establish that therapy improves function and makes people feel better. Health-related quality of life (HRQoL) refers to functioning and well-being in physical, emotional and social domains [3] .
Patients with systemic sclerosis (SSc) have functional disability [4] and generally poor HRQoL [5, 6] . This has been exemplified in clinical trials and observational cohorts. On average, patients with diffuse cutaneous (dcSSc) have greater impairments with physical functioning than those with limited cutaneous (lcSSc) SSc. This Points to Consider article focuses on HRQoL measures such as physical function, emotional wellbeing, pain, fatigue and sleep, and mouth handicap. Some measures are detailed in other sections (e.g. musculoskeletal, sexual function) and are not the focus of these recommendations.
In general, the trial should define a priori the target condition or symptom (e.g. physical disability, depressive symptoms), identify a study design [e.g. traditional parallel groups randomized controlled trial (RCT), cohort multiple RCT (mRCT)] and specify the duration of the study. The a priori specification of outcomes will be defined, including designation of the primary outcome variable with specification of the primary outcome measure, when it will be assessed and how it is to be scored (e.g. continuous, dichotomous with cut-off).
Web-based technology is particularly important in the case of rare diseases, such as SSc, where patients do not typically have access to specialized rehabilitation or psychosocial services. Online delivery of interventions to support HRQoL is increasingly common, and there are multiple examples where interventions for mental health conditions have successfully improved HRQoL [710] . An example is the ongoing trial of internet-based self-management vs educational book in improving self-efficacy in SSc (NCT02494401). We propose recommendations for Points to Consider in conducting clinical trials to improve functional disability in patients with SSc.
Valid primary outcome measures
Functional disability
HAQ-Disability Index
The HAQ-Disability Index (HAQ-DI) is an arthritis-targeted measure intended for assessing functional ability in arthritis [11] . It is a self-administered 20-question instrument that assesses a patient's level of functional ability and includes questions that involve both upper and lower extremities. The HAQ-DI score is determined by summing the highest item score in each of the eight domains and dividing the sum by eight, which results in a single score ranging from 0 (no disability) to 3 (severe disability). It has a 7-day recall period.
UK Functional Score
UK Functional Score is a self-administered 11-item functional questionnaire. It includes nine items relating to upper extremity function and two items relating to muscle weakness and lower extremity function [12] . The UK Functional Score is able to differentiate between lcSSc and dcSSc (P < 0.05) and is highly correlated with the HAQ-DI cross-sectionally (r = 0.90) and with change over time (r = 0.59) [13, 14] .
SF-36 physical component summary score
The SF-36 version 2 is a generic health status measure consisting of 36 items assessing the following eight domains [15, 16] : physical functioning (10 items), bodily pain (two) items], role limitations attributable to physical health problems (four items), general health perceptions (five items), mental health (five items), role limitations attributable to emotional problems (three items), vitality (four items) and social functioning (two items). The eight scales are summarized into Physical Component Summary (PCS) and Mental Component Summary (MCS) scores. The scales and summary scores are normalized to the US general population, for whom the mean score is 50 and the S.D. is 10.
PROMIS physical function domain
The National Institutes of Health Patient-Reported Outcomes Measurement Information System (PROMIS) Roadmap initiative [17] is a cooperative research programme designed to develop, evaluate and standardize item banks to measure patient-reported outcomes across common medical conditions [17, 18] . In addition to a single physical functioning score, upper extremity and mobility subdomain scores are available [19] . The PROMIS version 1.0 physical function item bank can be administered as a computerized adaptive test or using fixed short forms. It has been evaluated in SSc. A high correlation of 0.82 between PROMIS physical function scale and SF-physical functioning domain was found [20] . Table 1 provides some secondary and exploratory measures (in addition to primary measures) for RCTs that are applicable in functional disability, and may also be helpful to design trials in other aspects of HRQoL.
Study design and duration
The study should be double-blind, placebo (sham) controlled whenever possible (e.g. for a pharmacological intervention) to assess improvement in functional disability. It may be difficult to design a double-blind study if the study design involves physical or occupational therapy vs usual care. In this instance, the assessor should be blinded to the study arm.
When the objectives of a trial are pragmatic, the new cohort mRCT (cmRCT) design [37] , may be an advantageous option. Pragmatic RCTs are trials to test the effectiveness of an intervention in everyday practice with relatively unselected participants and in flexible conditions. They differ from explanatory trials in that pragmatic trials are meant to inform decisions about practice rather than explain mechanistic aspects of an intervention under ideal circumstances. In this respect, pragmatic trials are well suited to assess whether patients benefit from adding an intervention to treatment as usual, compared with treatment as usual only. Like explanatory trials, cmRCTs also include subjects with greater disease severity to prevent ceiling effects.
In the cmRCT design, an observational cohort is recruited, and patients complete a small set of core outcomes regularly. In addition to using their data as would normally be done in any longitudinal cohort, participants consent to allow their data to be used to identify them so they can be invited to participate in research interventions and compared with other patients participating in the cohort. The cmRCT design allows the conduct of multiple trials, drawing participants from the same cohort and thereby reducing costs dramatically. Other advantages include the ability to collect long-term outcome measures easily and a patient consent process that more closely replicates what occurs in real health settings.
Study duration
For a proof-of-concept trial, 36 months should be sufficient. This also allows for validation of the potential outcome measures. For regulatory purposes, we propose a trial duration of at least 1 year. This is based on the observation in RA, where regulatory agencies require trial durations of at least 1 year to provide a label of improvement in physical function. However, this is usually done as part of drug approval and not with a primary focus on HRQoL.
Inclusion and exclusion criteria
The study inclusion and exclusion criteria are minimum recommendations for these studies. Additional inclusion and exclusion criteria should be included for each trial design. 
TABLE 1
Health-related quality-of-life measures that meet the OMERACT criteria 
Inclusion criteria
We propose minimal standards to consider for the inclusion criteria. The authors are encouraged to revise or add additional items depending on the context of the study. Apart from general inclusion and exclusion criteria as outlined in Points to Consider [38] , specific inclusion criteria to consider are as follows: a HAQ-DI > 0.75 or SF-36 PCS < 45 or PROMIS physical function domain <45; and early dcSSc or lcSSc (defined by many as <5 years from first non-RP). Early dcSSc and early lcSSc are chosen because these individuals are more likely to change with an intervention, as these levels represent activity rather than damage [39] . Early is defined as <5 years from the first non-RP. It should be pointed out the 5-year criterion is arbitrary, but many consider that disease duration <5 years defines a group of patients with more reversible disease. Longer or shorter disease durations can be considered but should be data driven or fully justified.
Other inclusion criteria may be appropriate based on the primary objective. As an example, for a trial assessing hand function, the presence of moderate-to-severe hand contractures should be included, and primary outcome measures may be the Cochin Hand Function Scale and Hand Mobility in Scleroderma.
Exclusion criteria
Aside from the general exclusion criteria as outlined in the general Points to Consider [38] , the following should be considered for exclusion: patients with HAQ-DI 40.75 or SF-36 PCS 5 45 or PROMIS physical function 5 45 due to a possible floor or ceiling effect; moderate-to-severe cardiopulmonary disorders that may limit functional activities (if used, document involvement carefully); disease duration with irreversible changes or damage that could limit responsiveness (considered by some to be >57 years); and concomitant illnesses that either limit responsiveness or make it difficult to ascertain an effect (e.g. moderate-to-severe OA, large joint contractures, frozen shoulder, FM, depressed mood, chronic pain medications).
Statistical considerations
This can be derived from the overall Points to Consider [38] but should include descriptive statistics, as well as consideration of how change will be measured and reported; as a continuous variable, as a dichotomous variable or as the proportion of patients achieving the minimally important differences (Table 2) .
Conclusion
HRQoL and function are often compromised in SSc. In addition to the general considerations for all SSc clinical trials, there are factors to consider in clinical trials of HRQoL and function in SSc. There are a number of valid measures of HRQoL and function that can be used, including HAQ-DI, UK Functional Score, SF-36 PCS and PROMIS physical functioning domain. These measures can be primary measures or can be used as secondary or exploratory measures to supplement other objective measures. 
